SPR Supreme Resources Ltd.

Supreme Announces Proposed Name Change and Additional Line of Business

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 29, 2014) - SUPREME RESOURCES LTD. ("Supreme" or the "Corporation") (TSX-VENTURE:SPR) announces that it will, subject to regulatory approval, change its name to Supreme Pharmaceuticals Inc. in conjunction with its recent decision to pursue interests in pharmaceuticals or biomedical devices.

David Stadnyk, President, stated "The current management team of the Corporation has had highly successful experiences with finding and developing early stage pharmaceutical or biomedical devices, so given the moribund junior mining sector, we feel that if we can supply an additional line of business for Supreme, shareholders will benefit. Some of the pharmaceutical and biomedical companies that management has co-founded include Pharmaxis Ltd., Eupraxia Pharmaceuticals Inc. (of which Mr. Tsafalas is currently a financial executive), and Praxis Pharmaceuticals. We have no plans to dispose of or shelve our mineral exploration properties, and will continue to work on them as the opportunities present themselves. In the meantime, we are evaluating several significant opportunities to advance on in the pharma field."

About Supreme Resources Ltd.:

Supreme Resources Ltd. is a junior exploration company with advanced base and precious metals projects located in producing mining districts of British Columbia, Canada. Supreme Resources' goal is to increase shareholder value by developing exploration projects that have the potential of becoming new discoveries.

Website: www.supremeresourcesltd.com

Further news will be forthcoming in the near future.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States.

David StadnykPresident604.428.0511info@supremepharmaceuticals.com